Drug intelligence / Profile preview

liushenwan

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

Liushenwan is a traditional Chinese medicine (TCM) formula composed of six main ingredients: bezoar (gallstone of Bos taurus domesticus), musk (excretion of Moschus), cinobufagin toad venom (venenum bufonis), pearl (shell of Pernulo), realgar, and borneol[2][5]. It has been used historically for the treatment of infectious diseases such as influenza, tonsillitis, pharyngitis, mumps[5], sepsis[3], and more recently COVID-19[6]. Pharmacological studies indicate that Liushenwan exhibits broad-spectrum antiviral activity by inhibiting viral proliferation and modulating inflammatory responses through pathways such as NF-κB/MAPK and TLR4/NF-κB signaling. It also demonstrates anti-inflammatory effects by reducing cytokine levels like TNF-alpha and IL-1[3][8], antioxidant properties via lowering malondialdehyde content[3], immunomodulatory effects by enhancing macrophage phagocytosis[3], analgesic activity through inhibition of PI3K/Akt and TRPV1 signaling pathways[8], as well as antibacterial actions. Clinical trials have shown efficacy in improving outcomes in respiratory infections including influenza and COVID-19 by accelerating symptom resolution and viral clearance while maintaining a favorable safety profile[6].

Brand names
liushenwan
Other names
liu shen wan六神丸Liu-Shen-WanLiushen pillLiushen capsule
02

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)RK (Ribokinase)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on liushenwan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on liushenwan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call